Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fH1/DSP-0546LP Universal Influenza Vaccine Phase 1 Study
NCT06460064Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fH1 and DSP-0546LP in influenza (12 arms), sponsored by Sumitomo Pharma. Primary endpoints: Incidence of solicited local adverse events at 7 days, Incidence of solicited systemic adverse events at 7 days and 2 more. Started Jun 2024; status: completed.
02
Drugs
fH1DSP-0546LP
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06460064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06460064.